Journal: Scientific reports
This study used a Markov model to assess the cost-effectiveness of low-dose computed tomography (LDCT) lung cancer screening strategies for the Chinese population aged 40 to 80. It evaluated various starting ages and screening intervals.
The optimal strategy identified was triennial screening beginning at age 55. This approach demonstrated an incremental cost-effectiveness ratio (ICER) well below China’s 2019 per capita GDP threshold, indicating strong economic viability.
Sensitivity analyses showed that:
- Screening costs had the greatest impact on cost-effectiveness
- However, the overall findings remained robust
The study supports triennial LDCT screening from age 55 to 80 as the most cost-effective approach within the Chinese healthcare system.